A Phase 2/3 interventional study of Ulviprubart (ABC008) in Inclusion Body Myositis (IBM), sponsored by Abcuro, Inc.. Active, not recruiting at 21 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by Abcuro, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.
Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 2nd largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 2/3, and was the 34th registered.
65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.
Browse Myositis, Inclusion Body studies →4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Myositis International Health & Research Collaborative Alliance Foundation · Sites in United States
Ages 7+
Austin Neuromuscular Center · Sites in United States
Ages 45–75
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 2–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 9
First in 1990; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 270 is above the median of 30 across 42 interventional studies indexed under Myositis, Inclusion Body.
Median enrollment 24 across the 27 interventional studies, 59 across the 10 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 37 have an industry lead sponsor. The 10 most frequent:
Abcuro, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Abcuro, Inc. has 3 studies filed under Myositis, Inclusion Body — fewer than ten, so there is no comparison to draw.
2 of the studies in Myositis, Inclusion Body with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05046821University of California, IrvineSporadic Inclusion Body Myositis Natural History Study | 2027-03-31 |
| NCT06479863Austin Neuromuscular CenterEfficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis | 2027-05-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Myositis, Inclusion Body with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and:
ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and:
Subjects will be required to sign an informed consent form before undertaking any study-specific procedures or assessments. Screening is intended to be done at the final visit of the initial study, which will coincide with the Baseline (Day 1) Visit for this study; if this is not possible, the Baseline (Day 1) Visit for this study, including screening, may be conducted at a separate visit (provided it occurs within the visit window defined in Appendix 1 of the protocol). Subsequent study visits will occur every eight weeks until EOT at Week 156, or withdrawal from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Able to read, understand, and provide signed prior to the performance of any study-related procedures.
2. Has participated in and completed either Study ABC008-IBM-101 or Study ABC008-IBM-201; completion of the prior study will be defined as completion of the Part 2 (MAD) EOT Visit in Study ABC008-IBM-101 (subjects may have continued into Part 3 [MAD Extension]) or completion of the Week 80 Follow-up Visit in Study ABC008-IBM-201.
3. Demonstrated adequate compliance, in the opinion of the Investigator, with the study procedures during Study ABC008-IBM-101 or Study ABC008-IBM-201.
4. Willing and able to comply with the requirements of the protocol, including traveling to the site for study-related assessments and SC injections of ulviprubart.
5. Women of (WOCBP) and male subjects with female partners who are WOCBP (based on sex assignation at birth) must agree to use highly effective (\< 1% failure rate) for the duration of the study through 180 days after EOT/ETV.
6. WOCBP (based on sex assignation at birth) must have a negative urine pregnancy test at the Baseline (Day 1) Visit.
7. Male subjects (based on sex assignation at birth) must refrain from sperm donation for the duration of the study through 180 days after EOT/ETV.
Exclusion Criteria:
1. Has an unresolved AE or a clinically significant finding on a clinical laboratory test, , or physical examination during Study ABC008-IBM-101 or Study ABC008 IBM-201 that, in the Investigator's opinion, would limit the subject's ability to participate in or comply with this study.
2. Participation in another drug study (other than Study ABC008-IBM-101 or Study ABC008-IBM-201) within 30 days prior to the Baseline (Day 1) Visit or five times the half-life of the investigational drug, whichever is longer.
3. Is not willing or able to comply with the restrictions regarding the use of prohibited medications throughout the study.
4. Women who are pregnant, lactating, or who plan to become pregnant or initiate lactation during the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
Drug: Ulviprubart (ABC008)
All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
Primary Endpoint
The primary endpoint for the study will be the incidence, type, and severity of treatment-emergent adverse events (TEAEs). Safety as assessed by the incidence, type and severity of Treatment Emergent Adverse Events (TEAEs)
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Treatment Emergent Serious Adverse Events (TEASAEs)
Incidence, type, and severity of treatment-emergent serious adverse events (TESAEs)
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Treatment Emergent Adverse Events (TEAEs) onset within 24 hours of Study Medication Administration.
Incidence of TEAEs leading to study medication or study discontinuation
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Adverse Events of Special Interest (AESI)
Incidence of Adverse events of special interest (AESIs)
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Change from baseline standard laboratory parameters (Hematology)
Incidence of clinically significant changes in standard laboratory parameters (Hematology)
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Change from baseline in standard laboratory parameters (Chemistry)
Incidence of clinically significant changes from baseline in standard laboratory parameters (Chemistry)
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Change from baseline in standard laboratory parameters (Coagulation)
Incidence of clinically significant changes from baseline standard laboratory parameters (Coagulation)
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Inclusion Body Myositis Functional Rating Scale (IBMFRS)
Mean change from Baseline (Day 1) in IBMFRS over the duration of the study
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Manual Muscle Test 12 (MMT 12)
Mean change from Baseline (Day 1) in MMT 12 over the duration of the study
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Change from baseline in standard vital signs (respiratory rate)
Incidence of clinically significant changes in vital signs (respiratory rate)
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Change from baseline in standard vital signs blood pressure
Incidence of clinically significant changes in standard vital signs blood pressure (Systolic and diastolic) blood pressure)
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Change from baseline in standard vital signs (temperature)
Incidence of clinically significant changes in standard vital signs (temperature)
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Change from baseline in standard vital signs (pulse rate)
Incidence of clinically significant changes in standard vital signs (pulse rate)
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Counts of absolute and KLRG1+ lymphocytes by flow cytometry.
Blood samples will be collected for immunophenotyping. Counts of absolute and KLRG1+ lymphocytes and other lymphocyte subsets will be performed by flow cytometry.
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Presence and titer of antidrug antibodies (ADA)
The incidence and titers of ADAs to ulviprubart will be evaluated in blood samples
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Serum concentration of ulviprubart
Individual and mean serum concentration time profiles will be presented graphically using nominal time points.
Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Jan 2029, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ulviprubart
Abcuro, Inc.